AI Article Synopsis
- The study aimed to investigate how antisense oligonucleotides targeting telomerase RNA can inhibit the growth of human choriocarcinoma tumors in mice.
- Researchers transplanted JAR cells into female nude mice and treated them with different doses of antisense oligonucleotides, while monitoring tumor growth and telomerase activity.
- The findings showed significant tumor growth inhibition with antisense treatments, suggesting this method could be a new treatment strategy for choriocarcinoma, despite no major differences in effectiveness between dosage levels.
Article Abstract
Objective: To study the inhibitory effect of antisense oligonucleotides against telomerase RNA on the growth of human choriocarcinoma transplant in nude mice.
Methods: Choriocarcinoma xenografts were established by transplanting JAR cells subcutaneously to female nude mice, and were treated with high and low doses of antisense oligonucleotides. Control groups were treated with NS, random sequence and actinomycin D (Act-D). Tumor growth was monitored once every other day. Telomerase relative activity was assayed by TRAP-ELISA. Western blotting was used to detect expression of hTERT.
Results: Low and high doses antisense oligonucleotides, and Act-D inhibited tumor growth by 76.6%, 93.8% and 85.4% respectively, which were significantly different when compared with random sequence and NS groups. Expression of telomerase relative activity and hTERT were decreased as well. But the differences among the first three groups had no significance.
Conclusion: Telomerase RNA antisense oligonucleotide inhibits growth of human choriocarcinoma xenografts in nude mice. It may be a novel approach to the treatment of choriocarcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!